Key Quantitative Figures

  • Total Amount Raised: ₹26.025 crore (₹2602.50 lakhs)
  • Date of Fund Raising: 06 August 2025
  • Funds Utilized for Working Capital Requirements: ₹25.312 crore (₹2531.20 lakhs)
  • Funds Utilized for General Corporate Purposes: ₹0.713 crore (₹71.30 lakhs)
  • Total Funds Utilized: ₹26.025 crore (₹2602.50 lakhs)
  • Unutilized Amount: ₹0.00

Details of Fund Raising

The funds were raised through a Preferential Issue of 88,08,000 warrants at an issue price of ₹42.25 per share.

  • Initial Subscription: ₹9.3035 crore (₹930.35 lakh) was received as 25% subscription money upon the issue of warrants.
  • Subsequent Conversion: ₹16.7215 crore (₹1672.15 lakh) was received upon the conversion of 52,77,000 warrants into equity shares, representing the balance 75% conversion consideration.

Dates of Action and Review

  • Extraordinary General Meeting Approval: The objects for the fund raise were approved by shareholders in an EGM held on 23 July 2025.
  • Reporting Period: The statement covers the half-year ended 30 September 2026.
  • Filing Date: The disclosure was signed and dated 07 November 2026.

Parties Involved

  • Listed Entity: Shelter Pharma Limited (Scrip Code: 543963, ISIN: INE013V01011)
  • Auditors: The statement was reviewed by the company's Audit Committee and certified by Alvi & Associates, Chartered Accountants (Firm Registration No. 161053W). The audit partner was CA Aasim Alvi (M. No: 625878).

Purpose and Rationale

The purpose of the filing is regulatory compliance. The stated rationale is to confirm that the utilization of the proceeds from the preferential issue was in exact accordance with the objects stated in the EGM notice dated 26 June 2025 and approved by shareholders on 23 July 2025.

Financial and Operational Impact

As per the disclosure, there is no financial impact from a deviation or variation. The funds have been fully utilized exactly as intended and approved.

Auditor's Opinion

Alvi & Associates, Chartered Accountants, conducted an examination of the company's books and accounts. Based on their examination, they opine that the Statement of Deviation and Variation on Utilization of Funds is correctly extracted from the books of accounts for the period ended 30th September 2026.